Peptide Therapeutics Market, By Product Type (Branded Peptide and Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Feb 2023

Code : CMI1837

Pages :184

Formats :

Excel and PDF

Industry : Pharmaceutical

Peptide Therapeutics MarketSize and Trends

Global peptide therapeutics market is estimated to be valued at US$ 44,386.9 million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).

Therapeutic peptides is a unique class of pharmaceutical agents composed of series of amino acids, usually with molecular weights of 500-5000 Da. Since the synthesis of the first therapeutic peptide, insulin, in 1921, remarkable achievements have resulted in the approval of over 80 peptide drugs worldwide. Therefore, peptide drug development has become one of most important topics in pharmaceutical research industry/market.

Analysts’ Views on Global Peptide Therapeutics Market:

Global Peptide Therapeutics Market- Drivers

Increasing research and development activity

Peptide therapeutics is used in research and development of new drugs and therapies. Thus, increasing research and development activity by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in August 2022, an article published in Biomedicines, an open access journal, stated the use of peptide-based drug development for the development of different treatment options for cancer.

Figure 1.Global Peptide Therapeutics Market Share (%), By Product Type, 2023

Increasing prevalence of cancer

Peptide therapeutics technology is used for the treatment of cancer and thus increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, in December 2022, according to an article published by National Centre for Biotechnology Information (NCBI), estimated number of incident cases of cancer, in India, for the year 2022 was found to be 14, 61,427. In India, one in nine people are likely to develop cancer in his/her lifetime. Lung and breast cancers were the leading sites of cancer in males and females, respectively.

Figure 2. Global Peptide Therapeutics Market Share (%), By Region, 2023

Global Peptide Therapeutics Market- Regional Analysis

Among region, North America is expected to dominate the market over the forecast period, due to increasing adoption of organic growth strategies, such as product approvals by the governing bodies in the region in order to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in September 2022, Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the U.S. Food and Drug Administration (FDA) has approved DAXXIF (DaxibotulinumtoxinA-lanm) injection indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Europe is expected to dominate the market over the forecast period, owing to increasing adoption of inorganic growth strategies, such as acquisition by key players in the region to expand product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2022, UCB, a multinational biopharmaceutical company, acquired Ra Pharmaceuticals Inc., a clinical-stage Biopharmaceutical Company, to improve the treatment options for people living with myasthenia gravis and other rare diseases.